Table 1. Changes of patients’ data.
| Acarbose | P‐value | ||
|---|---|---|---|
| Before | 12 months later | ||
| n (male/female) | 22 (15/7) | ||
| Age (years) | 67 ± 8 | ||
| Duration of DM (years) | 5.9 ± 10 | ||
| Coronary risk factor | |||
| Hypertension, n (%) | 10 (45) | ||
| Dyslipidemia, n (%) | 6 (27) | ||
| Smoking history, n (%) | 4 (18) | ||
| Medication | |||
| Statin, n (%) | 5 (23) | ||
| ARB/ACE‐I, n (%) | 7 (32) | ||
| β‐blocker, n (%) | 2 (9) | ||
| Creatinine, mg/dL | 0.94 ± 0.21 | 0.98 ± 0.26 | 0.41 |
| BMI (kg/m2) | 23.4 ± 6.2 | 23.3 ± 6.7 | 0.52 |
| Blood pressure (mmHg) | |||
| Systolic | 134 ± 4 | 132 ± 8 | 0.43 |
| Diastolic | 74 ± 8 | 74 ± 5 | 0.27 |
| Heart rate (bpm) | 66 ± 8 | 65 ± 9 | 0.61 |
| Postprandial glucose (mg/dL) | 203 ± 42 | 141 ± 22 | 0.017 |
| HbA1c (%) | 7.6 ± 0.5 | 6.5 ± 0.4 | 0.011 |
| LDL cholesterol (mg/dL) | 127 ± 24 | 122 ± 29 | 0.35 |
| HDL cholesterol (mg/dL) | 45 ± 18 | 51 ± 14 | 0.42 |
| Triglyceride (mg/dL) | 154 ± 42 | 148 ± 35 | 0.23 |
ARB, angiotensin‐II receptor blocker; ACE‐I, angiotensin converting enzyme inhibitor; BMI, body mass index, DM, diabetes mellitus; HbA1c, glycosylated hemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.